Singleron Biotechnologies

Market position

Positions itself as a provider of complete, end-to-end single cell multi-omics solutions with an emphasis on clinical applicability, citing over 1 billion sequenced single cells, 9,000+ projects, 2,000+ sample types and 1,000+ supported scientific publications. Investor backing includes Tencent Holdings, ARCH Venture Partners, Lilly Asia Ventures, CDH Investments and others.

Offers an integrated workflow from tissue preservation through dissociation, partitioning, library preparation and bioinformatics rather than a single step; the SCOPE-chip microwell approach is presented as gentle on samples; preservation buffers permit up to three days between collection and processing, enabling off-site sample collection and clinical biopsy work; solutions are available in instrument-independent or automated formats.

Technology

Proprietary GEXSCOPE single cell system built on a microfluidic microwell SCOPE-chip for gentle single-cell partitioning, plus bead-based barcoding, tissue preservation buffers allowing sample storage for up to three days before processing, tissue dissociation instrumentation, library preparation chemistry and data analysis algorithms and databases. The company reports filing more than 100 patents, holding over 50 granted patents and more than 90 software copyrights, and licenses core microfluidic IP exclusively and worldwide from Yale University.

Go-to-market

Direct sales of kits, instruments and services from its own sites in Germany, China, Singapore and the United States, supported by regional distributors (DKSH in Australia/New Zealand) and certified service providers (Garvan Institute of Medical Research in Australia), plus scientific content marketing through webinars, publications, a learning center and a free bioinformatics academy.

Research institutes, hospitals and clinical laboratories, and pharmaceutical/biotech companies; the company states it collaborates with over 1,000 such organizations globally.

Geography

Offices, laboratories and manufacturing facilities in Cologne, Germany (Gottfried-Hagen-Str. 60-62, 51105 Cologne); Nanjing and Suzhou, China; Singapore; and Ann Arbor, Michigan and New Haven, Connecticut in the United States. Distribution coverage extends to Australia and New Zealand.

History

Founded in January 2018, the company expanded to offices, laboratories and manufacturing facilities in Cologne (Germany), Singapore, Nanjing and Suzhou (China), and Ann Arbor, Michigan and New Haven, Connecticut in the United States. It raised a Series A (September), Series A1 (November, more than $10M) and Series A2 (close to $30M, led by Tencent Holdings) within four months, totalling about $70M, and later closed an oversubscribed Series B of close to $100M. Its customer base grew from more than 200 institutions at the Series A1 stage to about 300 at Series A2 and over 1,000 laboratories by the Series B announcement. Recent activity includes a distribution partnership with DKSH for Australia and New Zealand (January 2026), designation of the Garvan Institute of Medical Research as an Australian certified service provider (January 2026), and announcement of the GEXSCOPE FFPE Single Nucleus Transcriptome Sequencing Kit (February 2026).

Risks & controversies

Not addressed in the available sources. Notable dependencies include the exclusive Yale University IP license underlying the GEXSCOPE system and the stated need to obtain regulatory approval for in vitro diagnostic products based on its single cell technologies.